Characterization of patients with atrial fibrillation not treated with oral anticoagulants

References

• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–67.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–1420.
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–10.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;137:263–72.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006;27:1954–64.
   Google Scholar
• Andersson P, Londahl M, Abdon NJ, Terent A. The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: Implications for anticoagulation prophylaxis. J Intern Med 2012;272:170–6.
   PubMed Web of Science ®Google Scholar
• Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke 2013; 44: 3103–8.
   PubMed Web of Science ®Google Scholar
• Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461–8.
   PubMedGoogle Scholar
• Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123:638–45.e634.
   PubMed Web of Science ®Google Scholar
• Turakhia MP, Hoang DD, Xu X, Frayne S, Schmitt S, Yang F, et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. Am Heart J 2013;165:93–101.e101.
   PubMedGoogle Scholar
• Baczek VL, Chen WT, Kluger J, Coleman CI. Predictors of warfarin use in atrial fibrillation in the United States: A systematic review and meta-analysis. BMC Fam Pract 2012;13:5.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs 2010;10:37–48.
   PubMed Web of Science ®Google Scholar
• Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: The risk–treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011;97:2046–50.
   PubMed Web of Science ®Google Scholar
• Norberg J, Bäckström S, Jansson J-H, Johansson L. Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clin Epidemiol 2013;5 475–81.
   PubMedGoogle Scholar
• Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest 2011;140:918–24.
   PubMedGoogle Scholar
• Marcucci M, Nobili A, Tettamanti M, Iorio A, Pasina L, Djade CD, et al. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. Eur J Intern Med 2013;24:800–6.
   PubMed Web of Science ®Google Scholar
• Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007;25:123–8.
   PubMed Web of Science ®Google Scholar
• Immonen S, Valvanne J, Pitkälä KH. The prevalence of potential alcohol–drug interactions in older adults. Scand J Prim Health Care 2013;31:73–8.
   PubMed Web of Science ®Google Scholar
• Bakken MS, Ranhoff AH, Engeland A, Ruths S. Inappropriate prescribing for older people admitted to an intermediate-care nursing home unit and hospital wards. Scand J Prim Health Care 2012;30:169–75.
   PubMed Web of Science ®Google Scholar
• Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit 2011;33:433–8.
   PubMed Web of Science ®Google Scholar
• Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation: A systematic review. Thromb Heamost 2013;110:213–22.
   PubMed Web of Science ®Google Scholar
• Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: Implications for stroke prevention. Circulation 2013;127:930–7.
   PubMed Web of Science ®Google Scholar